Mycoplasma hominis: Difference between revisions - Wikipedia

Tags: Mobile edit Mobile web edit

Line 52:

Oral tetracyclines have historically been the drugs of choice for use against urogenital and systemic infections due to ''M. hominis.''<ref name=":2" /> In locations and patient populations where tetracycline resistance or treatment failures are common, other drugs such as fluoroquinolones should be considered guided by ''in vitro'' susceptibility data when possible.<ref name=":2" />

Recent epidemiologic studies demonstrate that 18% of ''Mycoplasma hominis'' are resistant to ciprofloxacin and 61% are resistant to azithromycin. Resistance to minocycline is 6%.<ref>{{Cite journal |last=Pavoni |first=Matteo |last2=Principe |first2=Luigi |last3=Foschi |first3=Claudio |last4=Meroni |first4=Elisa |last5=Briozzo |first5=Elena |last6=Lazzarotto |first6=Tiziana |last7=Ambretti |first7=Simone |last8=Di Bella |first8=Stefano |date=2023-12-07 |title=Antimicrobial Resistance of Genital Mycoplasma and Ureaplasma : A Multicentre Study Over a 5-Year Period in Italy (2017–2021) |url=https://www.liebertpub.com/doi/10.1089/mdr.2023.0202 |journal=Microbial Drug Resistance |language=en |doi=10.1089/mdr.2023.0202 |issn=1076-6294}}</ref>

Some infections may be treated by a single antibiotic.<ref name=":2" /> In other cases such as severe ''M. hominis'' infections occurring in immunocompromised patients, combination of drugs usually active against the mycoplasmas have been recommended. In those cases, guidelines for optimal therapy remain to be established. Current therapeutic considerations are based only upon case reports.<ref name=":2" />